{"id":254124,"date":"2012-03-15T15:12:49","date_gmt":"2012-03-15T15:12:49","guid":{"rendered":"http:\/\/www.eugenesis.com\/biology-researcher-on-verge-of-major-breakthrough-in-drug-creation-process\/"},"modified":"2012-03-15T15:12:49","modified_gmt":"2012-03-15T15:12:49","slug":"biology-researcher-on-verge-of-major-breakthrough-in-drug-creation-process","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biology\/biology-researcher-on-verge-of-major-breakthrough-in-drug-creation-process.php","title":{"rendered":"Biology researcher on verge of major breakthrough in drug creation process"},"content":{"rendered":"<p><p>Public  release date: 14-Mar-2012  [ |   E-mail   |  Share    ]  <\/p>\n<p>    Contact: Steven Lenhert    <a href=\"mailto:lenhert@bio.fsu.edu\">lenhert@bio.fsu.edu<\/a>    850-645-9401    Florida    State University<\/p>\n<p>    New technology being developed at Florida State University    could significantly decrease the cost of drug discovery,    potentially leading to increased access to high-quality health    care and cancer patients receiving personalized chemotherapy    treatments.  <\/p>\n<p>    The details, which are spelled out in a recent publication of    the journal Biomaterials, outline the work of Steven    Lenhert, a Florida State biology assistant professor and    principal investigator on the research effort.  <\/p>\n<p>    \"Right now, cancer patients receive chemotherapy treatments    that are based on the accumulated knowledge of what has worked    best for people with similar cancers,\" Lenhert said. \"This is    the case because hospitals don't have the technology to test    thousands of different chemotherapy mixtures on the tumor cells    of an individual patient. This technology could give them    access to that capability, making the treatments truly    personalized and much more effective.\"  <\/p>\n<p>    The key to Lenhert's invention is miniaturizing the first phase    of a process used by pharmaceutical companies to discover new    drugs. Right now, these companies use large, specialized    laboratories to test hundreds of thousands of compounds on    different cell cultures in a process known as high throughput    screening. The equipment and manpower cost is substantial, even    though only a tiny fraction of the compounds will ever make it    to the next phase of testing.  <\/p>\n<p>    Lenhert's technology miniaturizes that process by printing all    of the compounds on a single glass surface and testing them on    cells using an innovative technique involving liposome    microarrays, which are basically collections of drug-containing    oil drops on a surface. If fully employed in the pharmaceutical    industry, this technology would make the cost of this expensive    process a thousand times cheaper, creating the potential for    personalized cancer treatments, lower-cost medicine and more    affordable, higher-quality health care options.  <\/p>\n<p>    \"In looking at the first phase of the drug-discovery process,    it struck me how, in this age of extreme miniaturization, we    are still using rooms full of robots and equipment to test drug    compounds,\" Lenhert said. \"It reminded me of the early days of    computers where you needed huge, room-spanning pieces of    hardware to do the most mundane tasks. I said, 'There has to be    a better way.'\"  <\/p>\n<p>    Lenhert's nanotechnology has been demonstrated as a proof of    concept on a small scale with cells commonly grown in    university laboratories. His research group is now working on    scaling their technology up to the high levels needed to    achieve medically relevant benefits. For personalized medicine    applications, the \"lab on a chip\" technology could then be    applied to cells obtained from patients through biopsies so    doctors can determine which drugs will work on a particular    patient. Depending on funding, Lenhert expects that the    technology could be made commercially available after two years    of development.  <\/p>\n<p>    \"We have taken an important first step in making liposome    microarray technology viable for the pharmaceutical and medical    industries,\" said Aubrey Kusi-Appiah, a graduate student in    Lenhert's research group and first author on the published    work. \"We have established that it can be done.\"  <\/p>\n<\/p>\n<p>Follow this link:<br \/>\n<a target=\"_blank\" href=\"http:\/\/www.eurekalert.org\/pub_releases\/2012-03\/fsu-bro_1031412.php\" title=\"Biology researcher on verge of major breakthrough in drug creation process\">Biology researcher on verge of major breakthrough in drug creation process<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Public release date: 14-Mar-2012 [ | E-mail | Share ] Contact: Steven Lenhert <a href=\"mailto:lenhert@bio.fsu.edu\">lenhert@bio.fsu.edu<\/a> 850-645-9401 Florida State University New technology being developed at Florida State University could significantly decrease the cost of drug discovery, potentially leading to increased access to high-quality health care and cancer patients receiving personalized chemotherapy treatments. The details, which are spelled out in a recent publication of the journal Biomaterials, outline the work of Steven Lenhert, a Florida State biology assistant professor and principal investigator on the research effort <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biology\/biology-researcher-on-verge-of-major-breakthrough-in-drug-creation-process.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":57,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[577690],"tags":[],"class_list":["post-254124","post","type-post","status-publish","format-standard","hentry","category-biology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/254124"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/57"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=254124"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/254124\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=254124"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=254124"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=254124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}